Alumis Q1 net loss $93.1M; Phase 3 envudeucitinib shows 68% PASI 90; NDA on track Q4 2026

ALUMIS INC.

2026-Q1 EPS reported -$0.74 revenue$1,741,000

Net loss $93.1M for Q1 2026; cash, equivalents and marketable securities $569.5M; runway into Q4 2027.
Phase 3 PsO: PASI 90 at Wk24: 68.0% and 62.1%; PASI 100: 41.0% and 39.5%; early quality-of-life improvements.
NDA submission for envudeucitinib in PsO on track Q4 2026; Phase 2b SLE topline data expected Q3 2026; TYK2 franchise update Q2 2026.
R&D expenses $81.5M (down from $96.6M); G&A $18.6M (down from $22.3M); exploring strategic alternatives for lonigutamab.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.